Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

SAGE / Sage Therapeutics, Inc. S-8

2018-02-22 sec.gov
S-8 As filed with the Securities and Exchange Commission on February 22, 2018 Registration No. 333-       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933     SAGE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter)       Delaware   27-4486580 (State or Other Jurisdiction of Incorporation or Organization)   (I. (19-0)

Sage Therapeutics' (SAGE) CEO Jeff Jonas on Q4 2017 Results - Earnings Call Transcript

2018-02-22 seekingalpha
Good morning, and welcome to Sage Therapeutics Fourth Quarter and Full Year 2017 Financial Results Conference Call. [Operator Instructions] This call is being webcast live on the Investors & Media section of Sage's website at sagerx.com. (19-0)

Sage Therapeutics 2017 Q4 - Results - Earnings Call Slides

2018-02-22 seekingalpha
The following slide deck was published by Sage Therapeutics in conjunction with their 2017 Q4 earnings call. (19-0)

SAGE / Sage Therapeutics, Inc. FORM 8-K (Current Report)

2018-02-22 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 22, 2018     Sage Therapeutics, Inc. (Exact name of registrant as specified in its charter)       DELAWARE   001-36544   27-4486580 (State or other jurisdiction of incorporation)   (Commission File Number)   (I. (19-0)

SAGE / Sage Therapeutics, Inc. 10-K (Annual Report)

2018-02-22 sec.gov
sage-10k_20171231.htm   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 10-K   (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from                      to                      Commission file number: 001-36544   Sage Therapeutics, Inc. (19-0)

Ligand Pharmaceuticals' (LGND) CEO John Higgins on Q4 2017 Results - Earnings Call Transcript

2018-02-22 seekingalpha
Good day. My name is Shikander [ph] and I will be your conference operator for today's call. At this time, I'd like to welcome everyone to Ligand's Fourth Quarter 2017 Earnings Release Conference Call. [Operator Instructions]. I now turn things over to Todd Pettingill, Director of Corporate Development and Investor Relations. (41-1)

Biotechs: Still Well Placed For More Gains

2018-02-20 seekingalpha
Big Pharma has to build out pipelines in new areas, and M&A is a compelling alternative. (719-3)

SAGE / Sage Therapeutics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Sage Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 78667J108 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.

SAGE / Sage Therapeutics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Sage Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 78667J108 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.

SAGE / Sage Therapeutics, Inc. / OPPENHEIMER FUNDS INC - FORM SC 13G (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*   Sage Therapeutics, Inc. (Name of Issuer)   Common Stock (Title of Class of Securities)   78667J108 (CUSIP Number)   12/31/2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this

SAGE / Sage Therapeutics, Inc. / OPPENHEIMER FUNDS INC - FORM SC 13G (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*   Sage Therapeutics, Inc. (Name of Issuer)   Common Stock (Title of Class of Securities)   78667J108 (CUSIP Number)   12/31/2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this

SAGE / Sage Therapeutics, Inc. FORM 8-K (Current Report)

2018-02-13 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 13, 2018     Sage Therapeutics, Inc. (Exact name of registrant as specified in its charter)       DELAWARE   001-36544   27-4486580 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.

SAGE / Sage Therapeutics, Inc. / Third Rock Ventures II, L.P. - SC 13G/A (Passive Investment)

2018-02-13 sec.gov
SC 13G/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)*     Sage Therapeutics, Inc. (Name of Issuer)     COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 78667J108 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☐ Rule

SAGE / Sage Therapeutics, Inc. / Third Rock Ventures II, L.P. - SC 13G/A (Passive Investment)

2018-02-13 sec.gov
SC 13G/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)*     Sage Therapeutics, Inc. (Name of Issuer)     COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 78667J108 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☐ Rule


CUSIP: 78667J108